14. A. Schedl et al., Nucleic Acids Res.
20, 3073–3077 (1992).
15. A. Schedl et al., Nucleic Acids Res.
21, 4783–4787 (1993).
16. A. Schedl et al., Nature
362, 258–261 (1993).
17. L. M. Weiner, J. Immunother. 29, 1–9 (2006).
18. R. Jefferis, Adv. Exp. Med. Biol.
564, 143–148 (2005).
19. R. Jefferis and J. Lund, Chem. Immunol.
65, 111–128 (1997).
20. M. A. Coccia and P. Brams, J. Immunol.
161, 5772–5780 (1998).
21. S. M. Santini et al., J. Exp. Med.
191, 1777–1788 (2000).
22. J. M. Carballido et al., Nat. Med.
6, 103–106 (2000).
23. R. Carlsson et al., J. Immunol.
148, 1065–1071 (1992).
24. C. Lapenta et al., J. Exp. Med.
198, 361–367 (2003).
25. M. Tary-Lehmann, A. Saxon, and P. V. Lehmann, Immunol. Today
16, 529–533 (1995).
26. A. R. T. Gerritsen et al., High Throughput Bio-Layer Interferometry in Therapeutic Antibody Discovery and Development
(ForteBio, 2010),
http://www.fortebio.com/documents/Genmab_Screening_Europe_2010.pdf, accessed Oct. 2012.
27. Octet Biosensors Product Insert, "Streptavidin High Binding Capacity Biosensors-Kinetics and Screening Grade," (ForteBio,
2007),
http://www.fortebio.com/documents/41-0046-PD_Rev_B_Streptavidin_High_Binding_PI.pdf, accessed Oct. 2012.
|
